Goldman Sachs Group Analysts Give Novartis (NOVN) a CHF 98 Price Target
Goldman Sachs Group set a CHF 98 price target on Novartis (VTX:NOVN) in a research note issued to investors on Friday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
NOVN has been the topic of several other research reports. JPMorgan Chase & Co. set a CHF 85 price target on Novartis and gave the stock a sell rating in a report on Friday, February 1st. Credit Suisse Group set a CHF 86 price target on Novartis and gave the stock a neutral rating in a report on Thursday, January 31st. Deutsche Bank set a CHF 96 price target on Novartis and gave the stock a neutral rating in a report on Wednesday, January 30th. UBS Group set a CHF 85 price target on Novartis and gave the stock a neutral rating in a report on Wednesday, January 30th. Finally, Kepler Capital Markets set a CHF 94 price target on Novartis and gave the stock a buy rating in a report on Wednesday, January 30th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company. Novartis has a consensus rating of Hold and an average target price of CHF 90.33.
Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.